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Abstract 
Introduction 
Outcome data on radiotherapy for prostate cancer in an elderly population are sparse.  The CHHiP 
trial provides a large, prospectively collected, contemporary dataset in which to explore outcomes 
by age. 
Methods and Materials 
CHHiP participants received 3-6 months of androgen deprivation therapy and were randomly 
assigned (1:1:1) to receive 74Gy in 37 fractions (conventional fractionation), 60Gy in 20 fractions or 
57Gy in 19 fractions. Toxicity was assessed using clinician-reported and patient-reported outcome 
(CRO/PRO) questionnaires. Participants were categorised as aged less than 75 (<75) or 75 years and 
older (75+).Outcomes were compared by age-group. 
Results 
491/3216 (15%) were 75+. There was no difference in biochemical or clinical failure (BCF) rates 
between the <75 and the 75+ group for any of the fractionation schedules. In the 75+ group BCF-free 
rates favoured hypofractionation and at 5 years were 74Gy: 84.7%, 60Gy: 91%, 57Gy: 87.7%.  The 
incidence of CRO (G3) acute bowel toxicity was 2% in both age-groups. Grade 3 acute bladder 
toxicity was 8% and 7%. Five year cumulative incidence of CRO grade 2+ late bowel side effects was 
similar in both age groups. However, in the 75+ group, there was a suggestion of a higher cumulative 
incidence of bowel bother (≥small) with 60Gy compared to 74Gy and 57Gy. Patient-reported bladder 
bother was slightly higher in the 75+ group than the <75 group and there was a suggestion of a 
lower cumulative incidence of bladder bother with 57Gy compared to 74Gy and 60Gy in the 75+ 
group which was not evident in those <75.  
Conclusion 
Hypofractionated radiotherapy appears to be well tolerated and effective in men over 75. The 57 Gy 
schedule has potential advantages in that it may moderate long term side effects without 
compromising treatment efficacy in this group. 
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Introduction   
Prostate cancer (PCa) is the most common cancer in men in the UK with 46,690 new cases and 
11,287 deaths in 2014 (1). Fifty-four percent of all new cases of prostate cancer are diagnosed in 
men aged over 70 years, with the highest incidence in men over 90 (1). Management options for 
localised disease include active surveillance in those with low-risk disease, external beam 
radiotherapy, radical prostatectomy, and watchful waiting in those not suitable for radical 
treatment.  
The Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy in Prostate 
Cancer (CHHiP) trial (CRUK/06/016) compared conventional and hypofractionated high-dose 
intensity-modulated radiotherapy (HFRT) for prostate cancer (2). The hypofractionated regimen of 
60 Gy in 20 fractions was shown to be non-inferior to the conventional fractionation of 74 Gy in 37 
fractions, supporting its use as a new standard of care for external beam radiotherapy for prostate 
cancer.  
Although age is not a factor in the likelihood of a patient completing radiotherapy (3), elderly 
patients are generally under-represented in clinical trials resulting in the lack of a robust evidence 
base (4, 5). The median age in the CHHiP trial was 69 years (range 44 to 85). This reflects the age-
related incidence of prostate cancer and the appropriate use of a patient’s performance status 
rather than age to direct treatment decisions. In this exploratory analyses of the CHHiP data we 
compare treatment outcomes in terms of time to biochemical or clinical failure and treatment 
related toxicity in patients categorised as less than 75 (<75) or 75 years and older (75+).    
 
Methods and Materials 
• Study design and randomisation 
The CHHiP study design has been described elsewhere (2). Briefly, men ≥16 years with a WHO 
performance status of 0 or 1 and histologically proven, T1b-T3aN0M0 prostate cancer were eligible. 
Patients with T3 tumours and a Gleason score ≥8, or a life expectancy of less than 10 years were 
ineligible. Initially, men with a prostate-specific antigen (PSA) ≤40 ng/ml and a risk of pelvic lymph 
node involvement of < 30 % were eligible, but this was revised in August 2006 to a requirement of 
PSA <30 ng/ml and a risk of seminal vesicle involvement of <30% to reflect the developing consensus 
of a need for long-term androgen deprivation (ADT) in men with locally advanced disease. The trial 
was reviewed by the London Multicentre Research Ethics Committee (04/MRE02/10) and was in 
accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki).  
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Men were randomised (1:1:1) to receive 74 Gy in 37 fractions over 7.4 weeks (conventional 
fractionation) or one of two hypofractionated regimens using daily fractions of 3 Gy; 60 Gy in 20 
fractions over 4 weeks or 57 Gy in 19 fractions over 3.8 weeks. Randomisation was stratified for 
National Comprehensive Cancer Network (NCCN) risk classification and treatment centre, but not 
patient age. It was not possible to mask patients or clinicians to treatment allocation. 
• Procedures 
3-6 months of ADT before and during radiotherapy was mandated in men with NCCN intermediate 
and high-risk disease, but was optional in those with low-risk disease. All radiotherapy was given 
using an intensity-modulated radiotherapy (IMRT) technique. Further details of the treatment and 
its quality assurance have been reported previously (2). PSA concentrations were recorded before 
commencing ADT and radiotherapy and then at weeks 10, 18, and 26 after radiotherapy and then at 
6-month intervals for 5 years and then annually. 
Acute and late toxicity was assessed using clinician-reported outcome (CRO) grading systems and 
patient-reported outcome (PRO) questionnaires. The Radiation Therapy Oncology Group (RTOG) 
system (6) was used to score toxicity every week during radiotherapy and at weeks 10, 12 and 18. 
Bowel, bladder and sexual function assessments were made before ADT and the start of 
radiotherapy and were graded according to the Late Effects on Normal Tissues: 
Subjective/Objective/Management (LENT/SOM) (7) and Royal Marsden Hospital (RMH) (8) scoring 
systems. Late toxicity was collected six monthly to 2 years and then annually to 5 years using all 
three toxicity scales. Men participating in a PRO substudy received questionnaires at baseline if they 
had not yet started ADT and all men received questionnaires pre-radiotherapy and at 10 weeks and 
6, 12, 18 and 24 months after the start of radiotherapy and then annually until 5 years. Further 
details of the PRO substudy are presented elsewhere (9). 
• Outcomes 
Biochemical or clinical failure (BCF) was the primary endpoint. The Phoenix consensus guidelines of a 
PSA concentration greater than the nadir plus 2 ng/ml (10) was used after 2007 and applied 
retrospectively to patients recruited before this date. Other recurrence (failure) events included 
recommencement of ADT, local recurrence, lymph node or pelvic recurrence and distant metastases. 
Acute toxicity was reported as the highest grade of bowel and bladder toxicity in the first 18 weeks 
from the start of radiotherapy. CRO late toxicity outcomes were reported using the time to first 
grade 2 or more toxic effect using the RTOG, LENT/SOM and RMH scoring systems. PROs of interest 
were time to first small or greater overall bowel bother and overall urinary bother reported as single 
items on the UCLA-PCI (11) and EPIC-50 (12) questionnaires. 
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• Statistical considerations 
All analyses presented are exploratory post-hoc subgroup analyses. As this was a non-randomised 
comparison, statistical comparisons were made for the baseline demographic data presented by age 
group (<75 and 75+) (T-tests, Mann-Whitney, chi
2 
and chi
2 
trend tests were used as appropriate). 
Kaplan-Meier methods were used to analyse time-to-event data. Comparisons of each 
hypofractionated regimen compared to 74Gy were made within each age group using the log-rank 
test. Hazard ratios less than 1 favoured hypofractionated radiotherapy. Acute and late toxicity data 
were analysed using the same methodology as previously described (2), with treatment comparisons 
made within each age group separately. Toxicity of grade 2 at five years from starting radiotherapy 
was of primary interest. Patient reported outcomes were analysed using the same methodology as 
previously described (9), small or greater bother was of primary interest. A significance level of 1% 
was used due to multiple testing.  All analyses were conducted using STATA version 13.0 and based 
on the primary analysis data snapshot taken on 8
th
 September 2015. 
 
Results 
• Baseline demographics 
Baseline demographics and medical history for patients in the <75 (n=2725) and 75+ (n=491) groups 
are shown in Table 1 and Supplementary Table 1. There was a significant difference (p<0.0001) in 
NCCN risk group distribution between the age groups with a higher proportion of intermediate-risk 
disease compared to low-risk disease in the 75+ group. The 75+ group had more Gleason 7 but fewer 
Gleason 6 cancers than the <75 group and the 75+ group had a larger maximum length of biopsy 
core involvement.   Median PSA levels were higher in the 75+ group (11.4ng/ml) compared with the 
< 75 group (9.8ng/ml p < 0.0001) but pre-hormone testosterone levels were similar. Prostate volume 
was larger in the 75+ group (median 42.7 cm
3
) compared to the < 75 group (median 37.0 cm
3
, p = 
0.001). More patients in the 75+ group compared with <75 had a previous transurethral resection of 
prostate (13% vs 7% respectively, p < 0.0001, see Supplementary Table 1).  IGRT use was similar in 
the two groups but more men in the <75 group received bicalutamide alone (p=0.014). 
• Time to biochemical or clinical failure 
There was no evidence of a difference in BCF between the two age groups (p=0.909) (Figure 1A). In 
the <75 age group, 5 year BCF-free rates were 88.9% (95% CI 86.5-90.9), 90.5% (88.3-92.3) and 
85.5% (82.8-87.8) in the 74 Gy, 60 Gy and 57 Gy groups respectively (Figure 1B). In the 75+ age 
group, 5 year BCF-free rates were 84.7% (77.3-89.9), 91.0% (83.7-95.1) and 87.7% (80.2-92.4) in the 
74 Gy, 60 Gy and 57 Gy groups respectively (Figure 1C). BCR-free rates for the 74Gy group were 
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slightly better in ≤75yr group compared with 75+ group (in keeping with less favourable presenting 
features in 75+ group) which seemed to be favourably modified by hypofractionation. (Figure 1C). 
• Acute toxicity 
The prevalence of clinician assessed bowel (Figure 2A) and bladder (Figure 2B) toxicity from week 1 
to week 18 was similar in the two age groups.  
There was no evidence of a difference in peak acute RTOG bowel toxicity (Figure 2A), between the 
age groups (p = 0.561) with 34/1859 (2%) and 5/289 (2%) of the <75 and 75+ groups experiencing 
grade 3 bowel toxicity, with no reported grade 4 bowel toxicity. Within the <75 age group, there was 
a significant difference in peak acute bowel toxicity between the control and both hypofractionated 
groups (p < 0.0001 for both 60 Gy and 57 Gy comparisons) although this did not reach statistical 
significance in the 75+ group (p = 0.097 and p = 0.054 for 60 Gy and 57 Gy); Supplementary Table 2. 
At 18 weeks, there was no significant difference in the distribution of the grade of acute bowel 
toxicity between age groups (p=0.274). 
There was no evidence of a difference in peak acute RTOG bladder toxicity (Figure 2B), between the 
age groups (p = 0.920). Grade 3 and 4 toxicity was recorded in 147/1859 (8%) and 21/1859 (1%) with 
20/289 (7%) and 2/289 (1%) in the <75 and 75+ groups respectively. Within the <75 age group, there 
was no significant difference in acute bladder toxicity noted between the control and either 
hypofractionated group (p=0.969 and p=0.569 for 60 Gy and 57 Gy groups respectively). However, 
within the 75+ age group there was more acute bladder toxicity in the control group than the 60 Gy 
group (p=0.004) but not 57 Gy (p=0.083); Supplementary Table 2. Differences had disappeared by 18 
weeks. 
• Late toxicity 
 
There was no evidence of a difference in time to first grade 2+ bowel toxicity using any CRO scale for 
either hypofractionated group compared to the control group in either age group (Figure 3).  The 5 
year cumulative incidences of grade2+ RTOG, RMH, and LENT-SOM bowel late side effects were 
similar with rates of 9.9% (95% CI: 8.8-11.2) / 12.5% (9.5-16.3) , 13.5% (12.2-14.9) / 12.9% (10.0-
16.6), 20.4% (18.8-22.1) / 20.4% (16.8-24.7) for the <75 and 75+ groups respectively (Figure 3). The 
prevalence of CRO late side-effects was stable over time from 1-5yrs with 2 year grade2+ RTOG, 
RMH and LENT-SOM bowel toxicity of 68/2430 (3%), 87/2413 (4%) and 131/2352 (6%) in the <75 
group compared with 12/413 (3%), 21/412(5%) and 29/401 (7%) in the 75+ group for the 74 Gy, 60 
Gy and 57 Gy schedules. (Supplementary Figures 1-3).  Patient-reported small+ bowel bother peaked 
at 10 weeks after the start of radiotherapy and was similar in both age groups (Supplementary 
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Figures 9-10). At 2 years, the prevalence of small+ bowel bother was 146/1159 (13%) and 28/153 
(18%) in the <75 and 75+ groups respectively remaining slightly higher in the 75+ group at all time 
points to 5 years (Supplementary Figures 9-10) when the cumulative incidences of small+ bowel 
bother were 32% (95% CI: 30-35) and 38% (32-44) in the <75 and 75+ groups.  However although 
there was no evidence of a difference between the fractionation schedules in the <75 group, in the 
75+ group there was a suggestion of higher cumulative incidence of small+ bowel bother with 60Gy 
compared to 74Gy (HR 1.44, CI 0.90-2.32, p=0.115) or 57Gy (HR 0.81, CI0.48-1.38), p=0.460) 
although this did not reach conventional statistical significance (Figure 5A).  
 
There was no certain evidence of a difference in time to first grade 2+ bladder toxicity using CROs for 
either hypofractionated group compared to the control group in either age group (Figure 4). 
However, there was a suggestion of increased RTOG toxicity with 60Gy in the <75 group (p=0.012). 
The 5 year cumulative incidences of grade2+ RTOG, RMH, and LENT-SOM bladder late side effects 
were similar with rates of 6.6 (95% CI 5.7-7.7) % / 9.2 (6.9-12.3) %, 25.9 (24.2-27.7) % / 32.1 (27.6-
37.0) % and 38.1 (36.1-40.1) % / 40.5 (35.7-45.7) % for the <75 and 75+ groups respectively (Figure 
4). The 2-year prevalence of grade2+ RTOG, RMH, and LENT-SOM bladder toxicity was 32/2430 (1%), 
193/2417 (8%) and 287/2346 (12%) in the <75 group compared with 8/413 (2%), 39/410 (10%) and 
54/399 (14%) in the 75+ group and were stable over time (Supplementary Figures 4-6). Grade 1 RMH 
bladder symptoms were persistently greater in the 75+ group both pre and post treatment 
(Supplementary Figure 5A).  Patient-reported small+ bladder bother peaked at 10 weeks after the 
start of radiotherapy and was similar in both age groups (Supplementary Figures 11-12). At 2 years, 
the prevalence of small+ bladder bother was 140/1154 (12%) and 33/149 (22%) in the <75 and 75+ 
groups respectively remaining slightly higher in the 75+ group at all time points to 5 years 
(Supplementary Figure 11-12) when the cumulative incidences of small+ bladder bother were 30% 
(95% CI: 28-33) and 39% (33-46) in the <75 and 75+ groups. However, although there was no 
difference between the fractionation schedules in the <75 group there was a suggestion of a lower 
cumulative incidence of small+ bladder toxicity with 57Gy compared to 74 Gy (HR 0.71, CI 0.43-1.16: 
p=0.163) or 60Gy in the 75+ group (HR 1.01, CI 0.63-1.62, p=0.953 (Figure 5B). 
 
At 2 years, the incidence of LENTSOM sexual dysfunction grade2+ was 1402/2189 (64%) and 
262/360 (73%) in the <75 and 75+ groups and 825/1255 (66%) and 109/161 (68%) respectively at 5 
years. The increased incidence of erectile dysfunction in the 75+ group pre-dated hormone and 
radiotherapy and persisted for the 5 years of follow-up (Supplementary Figure 7). There was no 
evidence of a difference in time to grade 2+ erectile dysfunction between the fractionation 
schedules in either age group (Supplementary Figure 8).  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
7 
 
Discussion   
The poor recruitment of older adults in to clinical trials is thought to be due to decline in functional 
reserve, increased comorbid conditions, lack of social support and the increased concomitant 
medications in elderly patients (13). When making decisions about their cancer treatment, older 
patients also have concerns about treatment-related discomfort, fear of side effects and transport 
issues (14). In an elderly population, the patient’s functional status and the presence of ‘geriatric 
syndromes’ such as dementia, depression, osteoporosis or falls are associated with increased 
chemotherapy toxicity (15). Data on radiotherapy outcomes and toxicity in an elderly population are 
sparse. 
In this post-hoc subgroup analysis of the CHHiP trial, there was no evidence of a difference in BCF in 
≤75 and 75+ groups. Results in the ≤75 group mirrored our previous report (2) with higher BCF rates 
in the 57Gy randomised trial arm. However, in the 75+ group both 60Gy and 57Gy showed higher 
(91.0% and 87.7% respectively) 5 year BCF-free outcome than 74Gy (84.7%) although this was not 
statistically significant. Equivalent results were seen in the 75+ group to ≤75 group despite less 
favourable features at presentation. This imbalance of prognostic factors between age groups may 
relate to clinician or patient preference for an active surveillance strategy with increasing age as 
observed previously In a Canadian population-based study (16). We are not aware of any previous 
evidence of a relatively beneficial effect of hypofractionated RT in older patients with PCa. This could 
have resulted from an imbalance of other unmeasured prognostic factors or perhaps slower or 
incomplete testosterone recovery.  Alternatively, it may be a chance finding due to the relatively 
small proportion of elderly patients (15% of the overall trial population). Although non-inferiority of 
57Gy compared with 74Gy could not be claimed formally in the whole trial population (5-year 
control rates of 85.9% vs 88.3%) the 57 Gy schedule has potential advantages in that it may 
moderate long term side effects without a meaningful compromise of treatment efficacy in elderly 
patients. The 57Gy schedule has been recently endorsed by NHS England Guidance for consideration 
in frail elderly patients (17).  
 
Previously one study in a mixed cohort of patients aged over 70 showed no increase in Grade 3 to 4 
toxicity in  more vulnerable or frail patients (5). To our knowledge, this is the first assessment of 
both CRO and PRO in elderly patients with PCa treated with HFRT. Whilst this was not a pre-planned 
analysis and results must be regarded as exploratory, the large number of patients recruited to the 
CHHiP trial permit some observations. There was no increase in peak acute bowel or bladder toxicity 
in the 75+ group compared with the ≤75 group and HFRT appeared well tolerated in elderly patients. 
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The difference in acute bowel toxicity between the control and HFRT groups seen in the < 75 age 
group (p < 0.0001 for both 60 Gy and 57 Gy comparisons) failed to reach statistical significance in the 
75+ group. This is reassuring but most likely relates to the smaller sample size in the 75+ group. 
Importantly 18 weeks after radiotherapy acute bowel toxicity had settled satisfactorily in both age 
cohorts with no differences between the fractionation schedules. With respect to acute bladder 
toxicity, there was a significant increase in RTOG grade 2+ toxicity between the control and 60 Gy 
group (p=0.004) but not the 57 Gy cohort (p=0.083) in the 75+ group. This difference was not seen 
for the <75 group (see Supplementary Table 2). This might reflect a higher incidence of pre-
treatment bladder dysfunction and support use of the 57 Gy in 19 fractions regimen in older men, 
particularly as this schedule was not associated with a decrease in treatment efficacy compared to 
74Gy or 60Gy. 
There were no consistent differences in prevalence or cumulative incidence of CRO late bowel 
toxicity up to 5 years after radiotherapy between the ≤75 and 75+ groups.  Similar findings were 
seen using conventional or HFRT and assessments with RTOG, RMH or LENT-SOM instruments. 
However, using PRO there was consistent increase in reporting of “bowel bother” in the 75+ group 
and this appeared to be most pronounced in the 60Gy group rather than 74Gy or 57Gy cohorts. 
Fractionation schedule was not related to bowel bother in the <75 group.  
There appeared to be more bladder symptoms in the 75+ group compared to the <75 group at 5yrs 
measured using the CRO instruments. This was confirmed using PRO and all degrees of “bladder 
bother” were increased in the 75+ group. Fractionation schedule appeared unrelated to “bladder 
bother” in the ≤75 group but 57Gy appeared to be associated with reduced “bother” scores in the 
75+ group rather than those treated by 74Gy and 60 Gy although this failed to reach statistical 
significance. Although it is difficult to separate treatment effects from an increase in urinary 
symptoms in an elderly population this might sound a cautionary note against dose escalation in 
more aged patients.  
Erectile dysfunction was increased post- treatment in the 75+ group.  This was expected as 
increasing age has previously been identified as a risk factor for erectile dysfunction following ADT 
and radiotherapy for prostate cancer (18). Higher levels of dysfunction were scored using the LENT-
SOM instrument than PRO assessing “bother” perhaps reflecting the change in importance of 
erectile dysfunction with increasing age. However post-ADT testosterone recovery may be delayed 
and incomplete in older patients. As having a normal testosterone level is important in the recovery 
of erectile dysfunction as well as other health issues, it is recommended that this should be assessed 
post-treatment (19). 
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Conclusions 
HFRT using 60 Gy or 57 Gy delivered in 3 Gy fractions appears to be well tolerated and effective in 
more elderly men and age should not be a barrier to implementing shorter radiotherapy schedules. 
The 57 Gy schedule has potential advantages in moderating long term bowel and bladder side 
effects whilst maintain satisfactory PCa control. 
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Table 1 - Table 1 Baseline demographics for patients <75 and ≥75 years old 
  
<75 
(N=2725) 
75+ 
(N=491) 
P-value 
No. % No. %  
Age 
Median (IQR) 67 (63-71)  76 (75-78)  
 
<0.0001 
Treatment group 
74Gy 
60Gy 
57Gy 
898 
925 
902 
33 
34 
33 
167 
149 
175 
34 
30 
36 
 
0.709 
NCCN risk group          
High Risk 321 12 64 13 <0.0001 
Intermediate Risk 1956 72 391 80  
Low Risk 448 16 36 7  
Intended hormone therapy          
LHRH+ short term AA 2264 84 436 89 0.014 
150mg Bicalutamide 357 13 46 9  
MAB 3 <1 2 <1  
Bicalutamide-other  2 <1 0 0  
LHRH alone 0 0 2 <1  
None 86 3 4 <1  
Gleason score          
≤6 975 36 147 29 0.018 
7 1668 61 327 67  
8 82 3 17 4  
Clinical T stage          
T1 1034 38 136 28 <0.0001 
T2 1452 53 314 64  
T3 236 9 41 8  
TX 1 <1 0 0  
Missing/Not done 1 <1 0 0  
Pre-hormone PSA (ng/ml)          
No. with data 2724 
 
490 
 
 
Median (IQR) 9.8 (7.0, 14.2) 
 
11.4 (8.6, 14.8) 
 
<0.0001 
Pre-hormone testosterone (nmol/L) 
No. with data 1114  146 
 
0.883 
Median (IQR) 12.6 (9.5, 16.2) 
 
12.3 (9.5, 16.4) 
 
 
Pre-hormone LH (iu/L)          
No. with data 1033 
 
123 
 
0.024 
Median (IQR), range 4 (3, 6) 1, 56 5 (3, 7) 
 
 
IGRT used           
Yes 
No 
825 
1686 
33 
67 
148 
304 
33 
67 
0.963 
Prostate volume (cm
3
)          
No. with data 936 
 
217 
 
0.001 
Median (IQR) 37.0 (28.0, 50.0) 
 
42.7 (30.3, 54.8) 
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Maximum length of core involvement (%) 
No. with data 
Median (IQR) 
  
1451 
35 (15, 60) 
  
 
  
289 
40 (20, 70) 
  
 
 
 
0.007 
Maximum length of core involvement (mm) 
No. with data 
Median (IQR) 
  
452 
9 (4, 17) 
  
 
  
92 
12 (7, 20) 
  
 
 
 
0.007 
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Figure 1 - Time to biochemical failure or prostate cancer recurrence (A) for <75 and ≥75 years old (B) <75 years old by treatment group (C) ≥75 years old by treatment group 
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898 877(3) 835(22) 785(30) 681(21) 438(14) 256(7) 153(2)74Gy
Number at risk (events)
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Years from randomisation
74Gy 60Gy 57Gy
HR60: 0.90 (0.69-1.18); p=0.463 
HR57: 1.34 (1.04-1.71); p=0.022 
HR60: 0.54 (0.28-1.05); p=0.064 
HR57: 0.64 (0.35-1.18); p=0.149 
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Figure 2 Prevalence of clinician assessed RTOG (A)  BOWEL and (B) BLADDER toxicity during week 1 to 18 from start of 
radiotherapy for <75 and ≥75 years old by toxicity grade 
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Figure 3 - Time to first grade 2+ BOWEL toxicity assessed by (A) RTOG, (B) RMH and (C) LENTSOM scales, for <75 and ≥75 
year olds by treatment group 
<75 age group      ≥75 age group 
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Figure 4 - Time to first grade 2+ BLADDER assessed by (A) RTOG, (B) RMH and (C) LENTSOM scales, for <75 and ≥75 year 
olds by treatment group 
<75 age group      75+ age group 
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Figure 5 -  Time to first small+ (A) BOWEL and (B) URINARY bother, for <75 and ≥75 year olds by treatment group 
  <75 age group      75+ age group 
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Summary  
The efficacy and toxicity of radiotherapy for localised prostate cancer in CHHiP trial participants aged 
75 and over was compared with patients younger than 75. There was no evidence of a difference in 
biochemical or clinical recurrence free survival or clinically significant toxicity between the older and 
younger patient groups. Hypofractionated radiotherapy is an effective and well tolerated treatment 
for localised prostate cancer in an elderly population with good performance status. 
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Supplementary Table 1 – Medical history for <75 and 75+ age group 
 
  
<75 
(N=2725) 
75+ 
(N=491) 
P-value 
No. % No. %  
Diabetes          
Yes 282 10 60 12 0.203 
No 2411 89 423 86  
Missing/unknown 30 1 8 2  
Hypertension          
Yes 1081 40 195 40 0.837 
No 1613 59 285 58  
Missing/unknown 29 1 10 2  
Inflammatory bowel disease          
Yes 102 4 22 5 0.414 
No 2584 95 458 93  
Missing/unknown 37 1 11 2  
Previous pelvic surgery          
Yes 215 8 37 8 0.824 
No 2470 91 443 90  
Missing/unknown 38 1 10 2  
Symptomatic haemorrhoids          
Yes 183 7 26 5 0.273 
No 2434 89 438 89  
Missing/unknown 104 4 26 5  
Previous TURP          
Yes 197 7 62 13 <0.0001 
No 2453 90 410 84  
Missing/unknown 69 3 17 4  
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Supplementary Table 2 – Acute Bowel and Bladder toxicity 
A - Acute Bowel Toxicity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B – Acute Bladder Toxicity 
 
 
 RTOG 
Grade 
Age <75 Age 75+ 
74Gy 
N (%) 
60Gy 
N (%) 
57Gy 
N (%) 
74Gy 
N (%) 
60Gy 
N (%) 
57Gy 
N (%) 
Worst 
acute 
score 
0 163 
(26) 
119 
(19) 
104 
(17) 
23 (25) 18 (19) 18 (18) 
1 308 
(50) 
266 
(43) 
279 
(46) 
45 (48) 40 (43) 42 (41) 
2 144 
(23) 
228 
(36) 
214 
(35) 
26 (28) 32 (34) 40 (40) 
3 6 (1) 13 (2) 15 (2) 0 4 (4) 1 (1) 
4 0 0 0 0 0 0 
P-value for 
comparison with 
74 Gy 
- < 
0.0001 
< 
0.0001 
- 0.097 0.054 
 RTOG 
Grade 
Age <75 Age 75+ 
74Gy 
N (%) 
60Gy 
N (%) 
57Gy 
N (%) 
74Gy 
N (%) 
60Gy 
N (%) 
57Gy 
N (%) 
Worst 
acute 
score 
0 55 (9) 70 (11) 51 (8) 13 (14) 3 (3) 14 (14) 
1 271 
(44) 
251 
(40) 
286 
(47) 
45 (48) 40 (42) 35 (35) 
2 240 
(39) 
248 
(40) 
219 
(36) 
33 (35) 42 (45) 42 (41) 
3 47 (7) 50 (8) 50 (8) 2 (2) 9 (10) 9 (9) 
4 8 (1) 7 (1) 6 (1) 1 (1) 0 1 (1) 
P-value for 
comparison with 
74 Gy 
- 0.969 0.569 - 0.004 0.083 
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Supplementary Figure 1 - Distribution of RTOG BOWEL toxicity at each assessment time (A) for <75 and ≥75 years old (B) <75 years old by treatment 
group (C) ≥75 years old by treatment group 
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Supplementary Figure 2 - Distribution of RMH BOWEL toxicity at each assessment time (A) for <75 and ≥75 years old (B) <75 years old by treatment 
group (C) ≥75 years old by treatment group 
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Supplementary Figure 3 - Distribution of LENTSOM BOWEL toxicity at each assessment time (A) for <75 and ≥75 years old (B) <75 years old by treatment 
group (C) ≥75 years old by treatment group 
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Supplementary Figure 4 - Distribution of RTOG BLADDER toxicity at each assessment time (A) for <75 and ≥75 years old (B) <75 years old by treatment 
group (C) ≥75 years old by treatment group 
 A       B      C 
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Supplementary Figure 5 - Distribution of RMH BLADDER toxicity at each assessment time (A) for <75 and ≥75 years old (B) <75 years old by treatment 
group (C) ≥75 years old by treatment group 
 A       B      C 
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Supplementary Figure 6 - Distribution of LENTSOM BLADDER toxicity at each assessment time (A) for <75 and ≥75 years old (B) <75 years old by 
treatment group (C) ≥75 years old by treatment group 
 A       B      C 
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Supplementary Figure 7 - Distribution of LENTSOM SEXUAL DYSFUNCTION toxicity at each assessment time (A) for <75 and ≥75 years old (B) <75 years 
old by treatment group (C) ≥75 years old by treatment group 
 A       B      C 
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Supplementary Figure 8 – Time to first LENTSOM SEXUAL DYSFUNCTION grade 2+ toxicity for (A) <75 years old by treatment group (B) ≥75 years old by 
treatment group 
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Supplementary Figure 9 - Distribution of patient reported BOWEL BOTHER at each assessment time (A) for <75 and ≥75 years old (B) <75 years old by 
treatment group (C) ≥75 years old by treatment group 
 A       B      C 
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Supplementary Figure 10 - Time to first very small+, small+ and moderate+ bowel bother event by 
age group 
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Supplementary Figure 11 - Distribution of patient reported URINARY BOTHER at each assessment time (A) for <75 and ≥75 years old (B) <75 years old by 
treatment group (C) ≥75 years old by treatment group 
 A       B      C 
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Supplementary Figure 12 - Time to first very small+, small+ and moderate+ urinary bother event 
by age group 
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